FibroGen (NASDAQ:FGEN) Earns Buy Rating from HC Wainwright

FibroGen (NASDAQ:FGEN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the company. StockNews.com started coverage on FibroGen in a research report on Thursday, February 13th. They issued a “hold” rating for the company. William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Trading Down 8.6 %

FGEN opened at $0.71 on Thursday. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.80. The firm has a 50-day moving average price of $0.52 and a two-hundred day moving average price of $0.43. The stock has a market capitalization of $71.13 million, a PE ratio of -0.57 and a beta of 0.75.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of FGEN. Two Sigma Securities LLC bought a new stake in shares of FibroGen during the 4th quarter worth approximately $27,000. Velan Capital Investment Management LP acquired a new position in FibroGen during the fourth quarter worth $42,000. XTX Topco Ltd raised its position in FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 77,693 shares in the last quarter. Franklin Street Advisors Inc. NC raised its position in FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 100,000 shares in the last quarter. Finally, FMR LLC lifted its stake in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares during the last quarter. 72.71% of the stock is owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.